|
|
|
|
Dr. Jörn Witt, LL.M. (London)
Lawyer
Counsel
|
CMS Hasche Sigle
Stadthausbrücke 1-3
20355 Hamburg, Germany
|
|
|
|
|
|
|
|
Jörn Witt is a counsel in the firm’s Intellectual Property and Lifesciences team located in Hamburg. He is also active in the firm's Competition Law group.
Jörn Witt regularly works both on contentious and non-contentious issues in relation to Intellectual Property, Unfair Competition and Competition Law. One of his main focus areas in Intellectual Property is advising major international clients from various sectors on their product piracy protection strategy. In this field, Jörn Witt also advises companies on effectively fighting illegal parallel imports and grey market trade.
His practise in the Lifesciences sector covers industries such as major international pharmaceutical corporations, medical device manufacturers as well as crop protection and nutrition companies. For these clients Jörn Witt in particular focuses on regulatory matters, contractual and sector-specific competition law issues. Likewise, Jörn Witt has broad experience in litigating for Lifesciences companies. Jörn Witt also has major expertise in the drafting and negotiation of business development contracts in the Lifesciences sector (inter alia Co-Marketing, Co-Promotion, Contract Manufacturing agreements) and of reimbursement agreements with health insurance funds.
|
|
|
|
Born 1976 in Reinbek. 1995 Abitur. Afterwards law studies in Hamburg. After the first state examination (2000) LL.M. course at University of London, Queen Mary College with scholarship of the Deutscher Akademischer Austauschdienst. 2001-2004 research assistant with Prof. Dr. Hubertus Gersdorf, University of Rostock. Afterwards Referendariat in Hamburg. 2006 second state examination. Also 2006 dissertation on a broadcasting law subject with a scholarship of the Studienstiftung des deutschen Volkes. Since 2006 with CMS Hasche Sigle.
|
|
|
|
- Internet-Aktivitäten öffentlich-rechtlicher Rundfunkanstalten, Duncker & Humblot 2007
- Unlautere Nachahmung eines Medizinproduktes – Femur-Teil, zugleich Anmerkung zum BGH-Urteil vom 15.4.2010 - I ZR 145/08; MPR 2011, 42
|
|
|
|
|